Cell Genesys to acquire Somatix for $250 mil.; combined company will have five development programs.
Executive Summary
CELL GENESYS $250 MIL. ACQUISITION OF SOMATIX WILL BUILD "GENE THERAPY POWERHOUSE," Cell Genesys CEO Stephen Sherwin, MD, declared in a Jan. 13 teleconference held to announce the signing of a definitive merger agreement. The combined company will have five gene therapy programs in development and the "largest patent portfolio in the gene therapy area," Sherwin maintained. The deal is expected to close in April.